|
Chronic Lymphocytic Leukemia
|
0.600 |
Biomarker
|
disease |
BEFREE |
Moreover, GEP of 7 homHCDR3 versus 6 nonhomHCDR3-IGHV3-21 CLLs yielded 20 differentially expressed genes, with WNT-16 being that expressed at the highest levels in homHCDR3-IGHV3-21 CLLs.
|
17148579 |
2007 |
|
Chronic Lymphocytic Leukemia
|
0.600 |
Biomarker
|
disease |
BEFREE |
Scandinavian patients with CLL have shown an overrepresentation of the poor-prognostic IGHV3-21 gene.
|
22464020 |
2012 |
|
Chronic Lymphocytic Leukemia
|
0.600 |
Biomarker
|
disease |
BEFREE |
We here investigated the prognostic impact of LPL expression in relation to other prognostic markers including IGHV3-21 usage in 140 CLL patients.
|
19709746 |
2010 |
|
Chronic Lymphocytic Leukemia
|
0.600 |
Biomarker
|
disease |
BEFREE |
Use of IGHV3-21 in chronic lymphocytic leukemia is associated with high-risk disease and reflects antigen-driven, post-germinal center leukemogenic selection.
|
18326815 |
2008 |
|
Chronic Lymphocytic Leukemia
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Clinically, co-occurrence of SF3B1 mutations and subset 2 BCR configuration prompts disease progression in IGHV3-21-CLL, whereas cooperation between NOTCH1 mutations, +12, and subset 8 BCR configuration invariably primes CLL transformation into Richter syndrome.
|
23637131 |
2013 |
|
Chronic Lymphocytic Leukemia
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
A significantly lower usage of IGHV1-69 and IGHV1-2 was documented, with comparable IGHV3-21 frequency (3% Chinese vs 3.8% Italian CLL).
|
26943037 |
2016 |
|
Chronic Lymphocytic Leukemia
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Subsets with "CLL-biased" homologous complementarity-determining region 3 (CDR3) were identified: (1) IGKV2-30-IGKJ2, 7 sequences with homologous kappa CDR3 (KCDR3), 5 of 7 associated with homologous IGHV4-34 heavy chains; (2) IGKV1-39/1D-39-IGKJ1/4, 4 unmutated sequences with homologous KCDR3, 2 of 4 associated with homologous IGHV4-39 heavy chains; (3) IGKV1-5-IGKJ1/3, 4 sequences with homologous KCDR3, 2 of 4 associated with unmutated nonhomologous IGHV4-39 heavy chains; (4) IGLV1-44-IGLJ2/3, 2 sequences with homologous lambda CDR3 (LCDR3), associated with homologous IGHV4-b heavy chains; and (5) IGLV3-21-IGLJ2/3, 9 sequences with homologous LCDR3, 3 of 9 associated with homologous IGHV3-21 heavy chains.
|
16076869 |
2005 |
|
Chronic Lymphocytic Leukemia
|
0.600 |
Biomarker
|
disease |
BEFREE |
<b>Purpose:</b> Unmutated (UM) immunoglobulin heavy chain variable region (IgHV) status or IgHV3-21 gene usage is associated with poor prognosis in chronic lymphocytic leukemia (CLL) patients.
|
29945996 |
2018 |
|
Chronic Lymphocytic Leukemia
|
0.600 |
PosttranslationalModification
|
disease |
BEFREE |
Here, we analyzed the global methylation profiles in CLL, by applying high-resolution methylation microarrays (27,578 CpG sites) to 23 CLL samples, belonging to the immunoglobulin heavy-chain variable (IGHV) mutated (favorable) and IGHV unmutated/IGHV3-21 (poor-prognostic) subsets.
|
19897574 |
2010 |
|
Chronic Lymphocytic Leukemia
|
0.600 |
Biomarker
|
disease |
BEFREE |
The first one (7 of 16 cases) carried a similar HCDR3 amino acid sequence (common-HCDR3 subset), virtually identical to the Scandinavian IGHV3-21 CLL.
|
15466924 |
2005 |
|
Chronic Lymphocytic Leukemia
|
0.600 |
Biomarker
|
disease |
BEFREE |
A striking exception to this rule was identified in CLL IGHV3-21-expressing cases: one amino acid was deleted from the CDR2 region in 16/63 (25.4%) mutated CLL IGHV3-21 sequences (including public database-derived IGHV3-21 CLL cases + the present series) vs. only 2/257 (0.78%) public database-derived mutated non-CLL IGHV3-21 sequences; 15/16 CLL IGHV3-21 sequences carrying this deletion belonged to a subset with unique, shared HCDR3 and light chain CDR3 motifs.
|
16783849 |
2006 |
|
Chronic Lymphocytic Leukemia
|
0.600 |
Biomarker
|
disease |
BEFREE |
Chronic lymphocytic leukemia (CLL) cells that use IgH encoded by IGHV3-21 and that have a particular stereotypic third CDR (HCDR3), DANGMDV (motif-1), almost invariably express Ig L chains (IgL) encoded by IGLV3-21, whereas CLL that use IGHV3-21-encoded IgH with another stereotypic HCDR3, DPSFYSSSWTLFDY (motif-2), invariably express κ-IgL encoded by IGKV3-20.
|
21525382 |
2011 |
|
Chronic Lymphocytic Leukemia
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Regarding clinical outcome: (i) UM CLL from the IGHV1-2/1-3/1-18/1-46/7-4-1/IGKV1-39 cluster had poorer prognosis than UM/M cases, or UM cases using the same IGHV genes but not in clusters; (ii) M CLL from the IGHV3-21/IGLV3-21 cluster had TTT similar to UM CLL, and shorter than M CLL expressing IGHV3-21 but not in cluster.
|
19036101 |
2009 |
|
Chronic Lymphocytic Leukemia
|
0.600 |
Biomarker
|
disease |
BEFREE |
Altogether, we show that TCL1 mRNA expression may predict clinical outcome in CLL and that the IGHV3-21 subset, regardless of mutational status, displays high TCL1 expression.
|
19889012 |
2010 |
|
Chronic Lymphocytic Leukemia
|
0.600 |
Biomarker
|
disease |
BEFREE |
Our data also provided new evidence supporting the prognostic relevance of separate IGHV genes or stereotyped BCR in CLL, namely: (a) a restricted non-mutated (UM) IGHV gene repertoire in CLL patients with autoimmune haemolytic anaemia (AIHA) (more frequent expression of UM IGHV1-69, IGHV3-11 and IGHV4-59 genes, P = 0.001), a shorter period of AIHA development for expressors of these genes (P = 0.001) and a tendency towards expression of a stereotypic HCDR3 (P = 0.029), (b) a high incidence of second solid tumour development in IGHV3-21-expressing patients (P = 0.005) and (c) differences in overall survival (OS) of UM CLL patients depending on the BCR structure.
|
21503826 |
2012 |
|
Chronic Lymphocytic Leukemia
|
0.600 |
Biomarker
|
disease |
BEFREE |
In conclusion, IGHV3-21 CLL should not be axiomatically considered a homogeneous entity with adverse prognosis, given that only subset #2 emerges as uniformly aggressive, contrasting non-subset #2/IGVH3-21 patients whose prognosis depends on IGHV mutational status as the remaining CLL.
|
25634617 |
2015 |
|
B-CELL MALIGNANCY, LOW-GRADE
|
0.310 |
AlteredExpression
|
disease |
BEFREE |
Comprehensive characterization of IGHV3-21-expressing B-cell chronic lymphocytic leukemia: an Italian multicenter study.
|
17148579 |
2007 |
|
Mantle cell lymphoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
In particular, older and more recent studies have demonstrated that MCL is characterized by a highly distinctive immunoglobulin gene repertoire with remarkable predominance of the IGHV3-21 and IGHV4-34 genes; restricted associations of IGHV, IGHD and IGHJ genes, culminating in the creation of quasi-identical ("stereotyped") heavy complementarity-determining region 3 sequences in roughly 10% of cases; and, very precisely targeted and, probably, functionally driven somatic hypermutation, ranging from minimal (in most cases) to pronounced.
|
21946621 |
2011 |
|
Mantle cell lymphoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
These latter findings are in favour of the hypothesis that IGHV3-21(+) tumours may represent a distinct MCL subentity and that there is a possible role for antigens in MCL development.
|
18452063 |
2008 |
|
Autoimmune hemolytic anemia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Our data also provided new evidence supporting the prognostic relevance of separate IGHV genes or stereotyped BCR in CLL, namely: (a) a restricted non-mutated (UM) IGHV gene repertoire in CLL patients with autoimmune haemolytic anaemia (AIHA) (more frequent expression of UM IGHV1-69, IGHV3-11 and IGHV4-59 genes, P = 0.001), a shorter period of AIHA development for expressors of these genes (P = 0.001) and a tendency towards expression of a stereotypic HCDR3 (P = 0.029), (b) a high incidence of second solid tumour development in IGHV3-21-expressing patients (P = 0.005) and (c) differences in overall survival (OS) of UM CLL patients depending on the BCR structure.
|
21503826 |
2012 |
|
Hairy Cell Leukemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Comparison of tumor with normal B-cell repertoires revealed preferential usage of IGHV3-21, IGHV3-30 and IGHV3-33 in hairy cell leukemia (p=0.001, p=0.003 and p=0.001, respectively).
|
18387977 |
2008 |
|
Neoplasms
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Comparison of tumor with normal B-cell repertoires revealed preferential usage of IGHV3-21, IGHV3-30 and IGHV3-33 in hairy cell leukemia (p=0.001, p=0.003 and p=0.001, respectively).
|
18387977 |
2008 |
|
Stereotypic Movement Disorder
|
0.010 |
GeneticVariation
|
phenotype |
BEFREE |
To investigate the IGHV3-21 frequency and the clinical impact of IGHV3-21 stereotypy, 337 newly diagnosed Swedish CLL patients from a population-based cohort were analyzed.
|
22464020 |
2012 |
|
Splenic Marginal Zone B-Cell Lymphoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
DNA methylation profiling was analyzed with the Infinium HumanMethylation27 array in 41 mature B-cell tumors, including 11 HCL, 7 splenic marginal zone lymphomas (SMZLs), and chronic lymphocytic leukemia with an unmutated (n = 7) or mutated (n = 6) immunoglobulin gene heavy chain variable (IGHV) region or using IGHV3-21 (n = 10).
|
30723113 |
2019 |
|
Leukemogenesis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Furthermore, approximately 50% of patients with IGHV3-21 carry stereotyped B-cell receptors, which implicate antigen selection in leukemogenesis.
|
22464020 |
2012 |